Objective . The aim of this study was to assess the effi cacy of oral methotrexate and tumor necrosis factor inhibitors in Japanese patients with active psoriatic arthritis. Methods . We retrospectively investigated 51 patients who fulfi lled the ClASsifi cation criteria for Psoriatic ARthritis (CASPAR) criteria for the effi cacy of tumor necrosis factor inhibitors and methotrexate. We assessed the visual analog scale score, psoriasis area and severity index score, C-reactive protein-based disease activity score in 28 joints (DAS28), swollen joint count (0 – 66), tender joint count (0 – 68), health assessment questionnaire score, C-reactive protein level, erythrocyte sedimentation rate, and matrix metalloproteinase 3, at both baseline and week 24. Results . Of the 51 patients, 34 were male and 17 were female, with a mean age of 50.3-13.2 years. The duration of psoriasis to onset of arthritis was 10.2-9.1 years. At week 24, in the group treated with the tumor necrosis factor inhibitor plus methotrexate, the tender joint count declined from 6.05-5.84 to 0.43-1.03, the swollen joint count declined from 6.42-4.36 to 0.00-0.00, and the DAS28 declined from 4.35-0.82 to 2.04-0.68. In the group treated with methotrexate alone, the tender joint count declined from 3.70-1.76 to 0.60-0.86, the swollen joint count declined from 5.26-4.00 to 0.27-0.70, and the DAS28 declined from 3.91-0.82 to 1.94-0.53. There were no signifi cant diff erences in the mean reduction in clinical measurements between the two groups. Conclusion . Our study demonstrated that methotrexate and tumor necrosis factor inhibitors are eff ective for the treatment of active psoriatic arthritis in Japanese patients.
ASJC Scopus subject areas